Wearable Medical Device Software (2026-2031) - Rising Adoption of Remote Patient Monitoring Drives Market Growth
Dublin, Aug. 21, 2026 (GLOBE NEWSWIRE) -- The "Wearable Medical Device Software - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" report has been added to ResearchAndMarkets.com's offering.
Wearable Medical Device Software Market to Reach USD 31.59 Billion by 2031 as Remote Patient Monitoring Accelerates
The global wearable medical device software market is projected to increase from USD 8.44 billion in 2025 to USD 10.40 billion in 2026 before reaching USD 31.59 billion by 2031. The market is expected to register a compound annual growth rate of 24.88% from 2026 to 2031, supported by expanding remote patient monitoring, chronic disease management programs, artificial intelligence integration and value-based care adoption.
Remote Patient Monitoring Reshapes Healthcare Delivery
Remote patient monitoring represented 27.6% of the application segment in 2025, making it the largest use case within the wearable medical device software market. Healthcare providers are increasingly adopting continuous monitoring platforms to extend patient oversight beyond hospitals and clinics, reduce unnecessary visits and identify signs of deterioration earlier.
Software platforms are becoming central to these programs by managing data collection, clinical alerts, reporting and patient communication. As wearable hardware becomes less differentiated, market value is shifting toward analytics, interoperability and workflow integration. Vendors capable of supporting large patient populations without increasing administrative burdens are expected to secure stronger positions in the expanding digital healthcare ecosystem.
Chronic Disease Management Creates Recurring Software Demand
Chronic disease management is forecast to grow at a CAGR of 26.1% through 2031. Demand is rising across diabetes, chronic kidney disease, cardiovascular disease, musculoskeletal pain and behavioral health programs, where continuous measurements can influence long-term treatment decisions.
The CMS ACCESS Model, which began enrolling Medicare beneficiaries on July 5, 2026, ties reimbursement to patient outcomes rather than service volume. This approach increases demand for wearable healthcare software that can identify emerging risks, support timely interventions and document measurable patient progress. Post-acute monitoring, medication adherence and sleep and stress tracking are also creating additional growth opportunities.
Artificial Intelligence Improves Clinical Utility
AI-enabled alerting, predictive analytics and risk scoring are strengthening the clinical value of wearable medical device software. These capabilities can help providers prioritize patients, forecast adverse events and move from retrospective data review toward proactive intervention. AI-enabled glucose forecasting is especially relevant in diabetes management, where continuous glucose monitoring data can guide treatment decisions.
However, alert fatigue remains a significant adoption barrier. A 2026 study of NHS remote patient monitoring deployments reported false-positive alert rates ranging from 74% to 99%. Excessive low-value notifications can contribute to clinician desensitization, workflow disruption and operational risk. Vendors are responding with patient-specific baselines and probability-based scoring, although healthcare organizations must continue balancing model performance against patient safety requirements.
Data privacy, cybersecurity, consent management and regulatory compliance also create structural costs for market participants. Successful platforms will need to combine accurate monitoring with secure data exchange, dependable connectivity and integration across electronic health record systems.
Software Leads Market Revenue
Software accounted for 78.2% of the component segment in 2025, reflecting the market's growing focus on applications, analytics, middleware and data management. Healthcare buyers increasingly prefer integrated platforms that can collect wearable data, analyze results, route information into clinical systems and support patient engagement through a unified environment.
Services continue to benefit from complex implementations involving multiple electronic health records and care platforms. Training, consulting, maintenance and technical support remain important because remote monitoring programs require stable connectivity, reliable reporting and clearly defined escalation workflows.
Smartwatches Lead While Continuous Glucose Monitoring Expands
Smartwatches held 31.2% of the device-type segment in 2025. Their large installed base and growing clinical acceptance for electrocardiogram, blood oxygen, activity and related monitoring functions provide software vendors with a scalable distribution channel.
Continuous glucose monitoring software-enabled devices are projected to grow at a CAGR of 26.2% through 2031. Diabeloop's DBLG2 system received CE marking in August 2025 and FDA clearance in December 2025 before launching commercially in Germany in July 2026. Reported real-world data showed Time in Range above 77% among Kaleido users. Patches, standalone ECG monitors, hearables, smart bands and smart clothing are also supporting specialized applications such as arrhythmia detection and continuous, low-burden monitoring.
North America Maintains Market Leadership
North America accounted for 39.1% of the wearable medical device software market in 2025. The United States leads the region due to its payer capacity, established digital health reimbursement pathways and provider readiness for remote monitoring. Canada and Mexico are also expanding hospital-based monitoring as digital care infrastructure develops.
Europe remains the second-largest regional market, led by Germany, the United Kingdom and France. Germany's DiGA pathway supports reimbursable digital health adoption, while GDPR requirements continue to shape cloud architecture, consent management and cross-border data strategies.
Asia-Pacific is expected to record the fastest regional growth, with a projected CAGR of 26.2% through 2031. A substantial chronic disease burden, rising digital health investment and government-led healthcare modernization are driving adoption across China, Japan and South Korea. The Middle East, Africa and South America remain at earlier stages of development but are positioned for expansion as connectivity improves and wearable devices become more affordable.
With remote patient monitoring, AI-powered analytics and outcomes-based reimbursement gaining momentum, the wearable medical device software market is transitioning from standalone tracking tools to integrated clinical platforms. Long-term growth will depend on vendors' ability to deliver accurate alerts, secure health data, reliable interoperability and measurable improvements in patient outcomes.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Oncology Imaging Demand
4.2.2 AI Assisted Protocol Optimization
4.2.3 Photon Counting and Spectral Precision Gains
4.2.4 Radiation Dose Reduction Pressure
4.2.5 Oncology Workflow Automation and Triage
4.2.6 Reimbursement Support for Quantitative Imaging
4.3 Market Restraints
4.3.1 High Capital Cost of Premium CT Platforms
4.3.2 Integration Burden Across PACS, RIS, and EHR Environments
4.3.3 Clinical Validation and Regulatory Friction for AI Features
4.3.4 Cybersecurity and Data Governance Concerns
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porters Five Forces
5 Market Size & Growth Forecasts
5.1 By Component
5.1.1 Hardware
5.1.2 Software
5.1.3 Services
5.2 By Deployment Mode
5.2.1 Conventional AI-Enhanced CT
5.2.2 Spectral CT
5.2.3 Photon-Counting CT
5.2.4 Interventional CT
5.3 By Application
5.3.1 Oncology Diagnosis and Staging
5.3.2 Tumor Monitoring and Treatment Response
5.3.3 Radiation Therapy Planning Support
5.3.4 Research and Clinical Trials
5.4 By End User
5.4.1 Hospitals
5.4.2 Diagnostic Imaging Centers
5.4.3 Cancer Treatment Centers
5.4.4 Academic and Research Institutes
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 India
5.5.3.3 Japan
5.5.3.4 South Korea
5.5.3.5 Australia
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles
6.3.1 Alphabet Inc. (Google Health / DeepMind)
6.3.2 Microsoft Corporation
6.3.3 NVIDIA Corporation
6.3.4 Siemens Healthineers AG
6.3.5 GE HealthCare Technologies Inc.
6.3.6 Koninklijke Philips N.V.
6.3.7 F. Hoffmann-La Roche Ltd
6.3.8 Tempus AI, Inc.
6.3.9 Aidoc Medical Ltd.
6.3.10 Qure.ai Technologies Private Limited
6.3.11 Heartflow, Inc.
6.3.12 PathAI, Inc.
6.3.13 Paige.AI, Inc.
6.3.14 Ada Health GmbH
6.3.15 AliveCor, Inc.
6.3.16 Butterfly Network, Inc.
6.3.17 Digital Diagnostics, Inc.
6.3.18 Lunit Inc.
6.3.19 Ibex Medical Analytics Ltd.
7 Market Opportunities & Future Outlook
7.1 White Space and Unmet Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/m7vnkt
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.